MTVA MetaVia Inc.
Price Chart
Executive Summary
MetaVia Inc. held its 2026 annual meeting on June 8, 2026, with stockholders approving five proposals including the re-election of two Class I directors, ratification of BDO USA as auditor, a reverse stock split (ratio range 1:5 to 1:22), a 200,000-share increase to the equity incentive plan, and an adjournment authorization. The reverse stock split authorization is the most consequential item for a $13M market cap company, as it aims to maintain Nasdaq listing compliance but signals the stock is distressed at these levels.
Actionable Insight
The reverse stock split authorization is a listing-compliance mechanism common for micro-cap biotechs trading near minimum bid-price thresholds. Monitor for the actual split ratio and execution date. The company has broad latitude (1:5 to 1:22), so the ultimate ratio will determine the post-split share count and float mechanics. No operational or financial updates were provided in this filing.
Key Facts
- Stockholders approved a reverse stock split at a ratio between 1:5 and 1:22, to be determined by the Board of Directors
- Stockholders approved an amendment to the 2022 Equity Incentive Plan, increasing authorized shares by 200,000 shares
- D. Gordon Strickland and James P. Tursi, M.D. were elected as Class I directors until the 2029 annual meeting
- BDO USA, P.C. was ratified as independent auditor for fiscal year ending December 31, 2026
- All five stockholder proposals were approved; quorum was 2,866,545 shares present and entitled to vote
- No financial results, guidance, or material financial data were included in this 8-K filing
Financial Impact
Reverse split authorization (1:5 to 1:22) signals Nasdaq listing maintenance effort for a $13M market cap biotech; equity plan increase of 200,000 shares represents modest potential dilution
Risk Factors
- Reverse split may not attract institutional interest and could lead to further price decline post-split
- With a $13M market cap, the company remains at risk of delisting if bid price does not stabilize
- Equity plan increase allows for further dilution via equity awards to management and employees
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-071358 |
| Document: tm2615356d2_ex10-1.htm | 0001104659-26-071358 |
| Document: 0001104659-26-071358-index-headers.html | 0001104659-26-071358 |
| Document: 0001104659-26-071358-index.html | 0001104659-26-071358 |
| Document: 0001104659-26-071358.txt | 0001104659-26-071358 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 8, 2026
4d ago
|
8-K
| $2.22 awaiting T+5 | awaiting T+5 | — | $1.74 (−21.62%) |
|
Jun 8, 2026
5d ago
|
8-K
| $2.22 awaiting T+5 | awaiting T+5 | — | $1.74 (−21.62%) |
|
May 27, 2026
17d ago
|
8-K
| $3.34 $2.71 | ▼ −18.86% | ▼ −20.07% | $1.74 (−47.90%) |
|
May 18, 2026
26d ago
|
8-K
| $1.11 $2.97 | ▲ +167.57% | ▲ +165.95% | $1.74 (+56.76%) |
|
May 14, 2026
29d ago
|
8-K
| $1.11 $3.85 | ▲ +246.85% | ▲ +245.88% | $1.74 (+56.76%) |
|
Apr 10, 2026
9w ago
|
8-K
| $1.41 $1.40 | ▼ −0.71% | ▼ −5.21% | $1.74 (+23.40%) |
|
Apr 7, 2026
9w ago
|
EFFECT
| $1.21 $1.49 | ▲ +23.14% | ▲ +17.81% | $1.74 (+43.80%) |
|
Mar 18, 2026
12w ago
|
8-K
| $1.48 $1.30 | ▼ −12.16% | ▼ −11.45% | $1.74 (+17.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access